SOURCE-LINKED STUDY SUMMARY
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Abstract summarizedQuality not appraised
- What was studied
- ACHIEVE-4 compared cardiovascular safety of oral orforglipron and insulin glargine.
- Who / model studied
- 2749 adults with diabetes, overweight/obesity and established cardiovascular or kidney disease.
- Studied dose & schedule
- Daily oral orforglipron up to 36 mg capsule-equivalent (17.2 mg tablet), versus daily titrated injectable insulin glargine; median follow-up two years.
- What the study found
- Major cardiovascular events: 4.2% versus 5.0%; HR 0.84 (95% CI 0.59–1.20). Noninferiority was met, not superiority. GI events: 62.1% versus 14.2%; significant/severe hypoglycemia: 6.8% versus 19.2%.
- Limitations & context
- Open-label, active-comparator trial with a wide confidence interval. Does not compare other incretins. Lilly-funded; abstract assessment only.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/S0140-6736(26)01865-9